Randomised controlled trials (RCTs) that compared moxifloxacin with beta-lactam-based standard therapy in patients with community-acquired pneumonia were eligible for inclusion. Trials had to report data on clinical treatment success, microbiological treatment success, mortality, and adverse events.
All included trials were multi-centre and conducted in adults; most trials were conducted in hospitalised patients. All trials administered oral moxifloxacin at a dosage of 400mg, in some trials this followed intravenous moxifloxacin. Beta-lactam-based regimens varied and included combinations of amoxicillin, clavulanic acid, roxithromycin, ceftriaxon, erythromycin, cefuroxime, azithromycin and levofloxacin, which were administered orally or intravenously at various dosages.
Two reviewers independently selected studies for inclusion.